2.59
+3.60%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Valneva
Its shares trade on Euronext Paris under the ticker VLA.PA. It has been listed since 28 June 2007. In the fiscal year to 31 December 2025, it reported revenue of €174.7m and a net loss of €115.2m. At that date it held total assets of €398.8m and shareholders' equity of €106.2m.
Valneva SE is a biotech company. The company is headquartered in Saint-Herblain, Pays De La Loire. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The firm has also vaccines in development, including candidates against Clostridium difficile and Lyme Borreliosis. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products. The company cooperates with various pharmaceutical companies using its technology platforms: EB66 vaccine production cell line and IC31 adjuvant. The firm has operations in France, Austria, Scotland, Canada and Sweden.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 28 Jun 2007
- Employees
- 508
- Website
- valneva.com ↗
Leadership
Pay as last reported
- Ms. Anne-Marie GraffinIndependent Chairman of the Board€116,600
- Mr. Thomas LingelbachPresident, Chief Executive Officer, Director, since 2012€999,105
- Mr. James SulatIndependent Vice Chairman of the Board, since 2013€107,225
- Mr. Peter BuehlerChief Financial Officer€640,021
- Mr. Vincent DequenneChief Operating Officer
- Ms. Petra PesendorferChief People Officer
- Dr. Hanneke SchuitemakerChief Scientific Officer
- Ms. Kendra WerginGeneral Counsel, Corporate Secretary
- Mr. Franck GrimaudChief Business Officer€454,191
- Dr. Juan JaramilloChief Medical Officer€584,775
- Ms. Dipal PatelChief Commercial Officer£314,150
- Ms. Mailys FerrereDirector, Representative of Bpifrance Participations SA
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 73
- Environment
- 77
- Social
- 89
- Governance
- 52
- Direct emissions (scope 1)
- 1,688 t
- Energy emissions (scope 2)
- 1,477 t
- Value chain emissions (scope 3)
- 1,586 t
- Women in the workforce
- 56.80473%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Valneva SE possesses a robust research and development division that enables the company to continuously innovate and develop new vaccines. This strength gives Valneva a competitive advantage in the pharmaceutical industry.
- Valneva SE offers a wide range of vaccines, targeting various diseases and conditions. This diverse product portfolio reduces the company's dependence on a single product or market, minimizing the risk associated with product failure or market fluctuations.
Weaknesses
- Compared to some of its larger competitors, Valneva SE has a smaller market share in the pharmaceutical industry. This could limit the company's resources and ability to compete in terms of marketing and distribution.
- Valneva's presence is primarily concentrated in certain regions, which could pose challenges when expanding into new markets. Increased geographical diversification could provide more growth opportunities.
Opportunities
- The global demand for vaccines is expected to continue growing due to increasing awareness about preventive healthcare. Valneva SE can leverage this opportunity to expand its market share and revenue potential.
- Valneva SE can explore strategic partnerships and collaborations with other pharmaceutical companies, research institutions, or governments to enhance its research capabilities, access new markets, and strengthen its competitive position.
Threats
- The pharmaceutical industry is highly competitive, with numerous companies vying for market share. Valneva SE faces the possibility of increased competition from existing and emerging players, which could impact its market position and profitability.
- As a vaccine manufacturer, Valneva SE operates in a regulatory environment that imposes strict guidelines and standards. Failure to comply with these regulations could result in delays or disruptions in product development and approval processes.
- Valneva SE may be exposed to economic fluctuations, especially if there is a global economic downturn. Reduced consumer spending power and budget constraints on healthcare expenditures could affect the demand for vaccines and potentially impact the company's financial performance.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.